Astrazeneca Korea Co. Ltd. will pull its blockbuster diabetes drug, Forxiga (dapagliflozin), from the South Korean market, a company official confirmed to BioWorld, citing “multiple factors” like ...

AstraZeneca’s SGLT2 diabetes drug Forxiga has another approval to celebrate. The drug, known as Farxiga in the U.S., gained a nod in Europe to treat patients suffering from heart failure with any type ...

AstraZeneca has filed a patent suit against Pharmacor over its plans to list a generic version of AstraZeneca’s blockbuster diabetes drug Forxiga on the PBS, but will have to defend the validity of ...

The European Commission (EC) approved AstraZeneca (NASDAQ:AZN) Forxiga for expanded use to treat heart failure (HF) with reduced ejection fraction (HFrEF) to cover patients across the full spectrum of ...